BIOMARKERS & PRECISION MEDICINE US 2025

October 27-28, San Francisco, USA

Conference Brochure



Book Now!

Complimentary Guest Passes are Available

Register

Sponsor

Pioneering The Future Of Biomarkers & Precision Medicine

13 Content Tracks Across Two Days

10+ Hours of pre-arranged 1:1 Meetings

30+ Partners

1,000+ Attendees

Composed of 3 Groundbreaking Programmes!

- **Biomarkers**
- **Spatial Biology for Precision Medicine**
- **Digital Pathology & AI**

Over 130 Industry-Leading Speakers Including...

KEYNOTE SPEAKER

LEROY HOOD,
Co-Founder, Institute of Systems Biology

Don't Miss His Keynote at 08.40 on Day 1:
The Synergy Of Data-Driven Health And Data-Driven Peptide Drug Discovery

KEYNOTE SPEAKER

IDA SIM,
Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley); Co-Director, UCSF UC Berkeley Joint Program in Computational Precision Health

Ida Will Open Day 2 of The Meeting At 9.00 With A Talk On *Harnessing Computational Tools In Precision Medicine: Implementation & Future Directions*

PANEL DISCUSSION

IVDR REGULATIONS & THEIR IMPACT

Join Us For The Interactive Panel Discussion On Day 1 At 11.55 With The Panellists Below:

BRIAN BAKER, Executive Director - Regulatory Affairs & in Vitro Diagnostics, Regeneron

ANDREA RENNINGER, Senior Director, Regulatory Affairs - Companion Diagnostic, Daiichi Sankyo

AI-POWERED PRECISION MEDICINE

Keep Up To Date With The Latest AI Applications With This Special Plenary Panel On Day 2 At 12.35

IDA SIM, Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley), UCSF Chief Research Informatics Officer, Co-Director, UCSF UC Berkeley Joint Program in Computational Precision Health

MIKE MONTALTO, Vice President, Precision Medicine, Global Development, Amgen

WELCOME TO

Biomarkers & Precision Medicine US 2025

Welcome to Biomarkers & Precision Medicine US 2025, Oxford Global's flagship US event bringing together the leading innovators in Precision Medicine at the Westin St. Francis San Francisco on Union Square, October 27–28.

Join us for two immersive days of expertly created content addressing the most pressing challenges, spotlighting breakthrough innovation, and uncovering emerging technologies across three cutting-edge programmes: Biomarkers 2025, Spatial Biology for Precision Medicine, and Digital Pathology & AI.

Engage in high-level discussions and expertly tailored sessions that showcase the latest advancements in biomarker driven research, spatial multi-omic analysis, and digital pathology. Our carefully crafted agenda highlights pioneering developments driving the future of diagnostics and therapeutic innovation. Hear cutting edge insight from leading experts as they explore the integration of spatial and multi-omic insights into biomarker development, the role of AI in transforming pathology workflows, and evolving strategies for regulatory success around IVDR and latest developments in companion diagnostics. Sessions will also examine how these technologies are shaping clinical decision-making, enhancing patient stratification, and advancing precision-guided therapies.

In addition to groundbreaking scientific presentations and interactive discussions, this event offers invaluable opportunities to network with industry leaders, cutting-edge technology providers, emerging innovators and key investors. Explore our vibrant exhibition room, start-up zone and join exclusive plenary keynotes, panel discussions and fireside chats with renowned authorities taking place in track 1.

Don't miss the chance to connect with key industry leaders and stay at the forefront of the next-generation advancements set to transform precision medicine.

Mike Burden
Director of Production & Content – Precision Medicine Brand,
Oxford Global

Unlock The Latest News & Insights

Sign up for our monthly newsletter to keep up with all things Precision Medicine

Click Here

Book Now

WHAT'S NEW

Benefits Of Attending

Unified Vision for Precision Medicine
The latest developments in Biomarkers, Spatial Biology, and Digital Pathology research come together under one roof to drive forward precision medicine. Together, these complimentary fields offer a comprehensive approach to advancing patient care and fostering collaboration across disciplines.

Stay ahead of evolving regulatory landscapes and navigate IVDR regulations with talks, panel discussions & roundtables focused on providing direction to this conundrum.

Gain exclusive insights into cutting-edge biomarker research
Explore the latest in biomarker discovery, validation, and clinical implementation across oncology, neuroscience, immunology, rare diseases etc.

Gain exclusive insights into cutting-edge biomarker research - explore the latest in biomarker discovery, validation, and clinical implementation across oncology, neuroscience, immunology, rare diseases etc.

Unlock the potential of AI - discover how AI-powered biomarker analysis, spatial biology, and digital pathology are revolutionizing drug development, patient stratification & Image analysis.

Interdisciplinary learning is key to driving Precision Medicine
Join dynamic plenary panel discussions bringing together experts across biomarkers, diagnostics, genomics, and AI to explore collaborative innovation and real-world application.

Engage with thought leaders in translational research
Gain firsthand insights from leading scientists, clinicians, and regulatory experts on biomarker adoption, clinical trial design, and strategies for precision medicine implementation.

Discover groundbreaking biomarker technologies shaping the future
Deep dive into mass spectrometry, flow cytometry, multiplex imaging, and single-cell sequencing techniques advancing biomarker analysis.

Explore omics technologies & diagnostics driving research
Sessions will address cfDNA, ctDNA, CTCs, proteomics, metabolomics and transcriptomics.

DON'T MISS THESE

Interactive Panels

BIOMARKERS

Challenges In Translating Exploratory Biomarkers Into The Clinic

IVDR Regulations & Their impact

Application and Integration of AI/ML in Biomarker Science

Application & Integration Of Proteomic Biomarkers In Precision Medicine

Implementing Patient-Centric Biomarkers In Clinical Trials

PRECISION MEDICINE

AI-Powered Precision Medicine

Building The Next Era Of Precision Medicine: Stakeholder Collaboration Across Biomarkers, Diagnostics, Genomics & Therapeutic Innovation

DIGITAL PATHOLOGY

Building A Business Case For Digital Pathology

Real World Learning From Deploying Digital And Computational Pathology At Scale

Digital Pathology in Pharma – Overcoming Integration Strategies & Future Proofing

SPATIAL BIOLOGY

Addressing The Future Needs Of Spatial Multi-Omics

Data Sharing And Reproducing Analyses In The World Of Spatial Transcriptomics

Moving Towards Clinical Trial & Discovery Phases

Computational Methods To Assist In The Identification, Classification & Visualization Of Complex Multi Model Datasets

SPECIAL EVENT FEATURES

Big Attendance Meets Intimate Connections

Day 2 Breakfast Roundtables & Workshops

Mark your calendars for our exclusive cross-programme roundtables on day two of the event. Join in from 8:15 – 9:00am to discuss key topic areas with one of our experts in a lively informal setting whilst you enjoy a coffee & a pastry before the day ahead.

– Day One & Two –

Plenary Panel Discussions

Don't miss our exclusive Plenary Panel Discussions taking place on the main stage. Join leading experts and industry innovators as they tackle the critical themes shaping the future of precision medicine. These dynamic, interactive sessions will explore the latest breakthroughs and challenges in biomarker development, AI integration, and personalized healthcare.

Plenary Panel Discussion Session 1: Building the Next Era of Precision Medicine

Discover how cross-sector collaboration between biomarker developers, diagnostic innovators, genomic scientists, and therapeutic leaders is driving the next wave of precision medicine breakthroughs.

Plenary Panel Discussion Session 2: AI-Powered Precision Medicine:

Gain insights into the transformative role of AI in personalizing patient care, and explore the real-world challenges of integrating AI into clinical workflows.

Day One - Opening Keynote Address

Leroy Hood, Co-Founder, Institute of Systems Biology

A visionary in biotechnology and one of the founding figures of systems biology & precision mediicne, Leroy Hood will deliver a compelling keynote exploring the synergy between data-driven health and peptide drug discovery. His talk will delve into how integrated, longitudinal phenome and genome analysis can unlock personalized insights to drive wellness, healthy aging, and disease prevention, reshaping the future of individualized healthcare.

He will also highlight emerging innovations in peptide drug discovery, where large-scale DNA synthesis and high-throughput screening are accelerating the development of targeted therapeutics. This session will showcase how these two powerful approaches—preventative, data-led healthcare and next-generation drug discovery—can be harnessed together to redefine the future of precision medicine.

Day Two – Opening Keynote Address

Ida Sim, Professor of Medicine, UCSF; Co-Director, UCSF-UC Berkeley Joint Program in Computational Precision Health

A trailblazer at the intersection of technology, data science, and medicine, Ida Sim will take the stage to explore the transformative impact of computational tools in precision medicine. Her keynote will examine how AI, data integration, and digital infrastructure are being implemented to support scalable, personalized healthcare solutions across clinical and research environments.

Drawing on her leadership in the UCSF-UC Berkeley Joint Program in Computational Precision Health, she will highlight real-world use cases and discuss what's next for the field—from predictive modeling and real-time analytics to the ethical, regulatory, and equity considerations surrounding data-driven medical practice. This session will chart a course for the future of computational precision medicine and its role in advancing healthcare at scale.

WHY PARTNER WITH

OXFORD GLOBAL?

At Oxford Global, our mission is to curate personalised experiences that foster community and inspire innovation.

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

Arrange 1-1 Meetings

Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

Speaking Opportunities

Showcase your company's recent work to a relevant and highly engaged audience.

Host Panel & Roundtable Discussions

Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

Organise Workshops

Demonstrate best practice within the industry in front of your peers with case studies from your clients.

Exhibit your Products & Solutions

Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

Digital Marketing & Lead Generation

Accessing the Oxford Global database, amplify your thought leadership and branding messaging through our digital content initiatives.

LEARN MORE

DRIVE INNOVATION & ACCELERATE RESEARCH

Who Is Partnering?

Platinum Sponsor

10x GENOMICS

Gold Sponsors

ariadne.ai
BRUKER
KANVAS
Miltenyi Biotec
Olink
PRECISION for medicine
SINGULAR GENOMICS
SYNCELL

Silver Sponsors

AKOYA BIOSCIENCES
biodesix
BIOIVT
CONCEPT LIFE SCIENCES
DISCOVERY LIFE SCIENCES
ENABLE MEDICINE
HAMAMATSU
LEVITAS BIO
Lunaphore
mission bio
STANDARD BIOTOOLS
vizgen

Bronze Sponsors

Cerba Research
BIOGNOSYS
NEXT GENERATION PROTEOMICS
ELUCIDATE BIOTECHNOLOGIES
Leica MICROSYSTEMS Leica BIOSYSTEMS
MILLIPORE SIGMA
RARECYTE

Network & Programme Sponsors

Ardigen
ALMAC
CROWN BIOSCIENCE
EMLES
FYR
nomic
PIXELGEN TECHNOLOGIES
PROSCIA
proteome sciences
RULES BASED MEDICINE
an IQVIA business

AGENDA AT A GLANCE

Biomarkers

Join world-leading experts in biomarker research and development for this in-person meeting in the heart of San Francisco. Discover groundbreaking insight into biomarker science, patient stratification, companion diagnostics, regulatory considerations, clinical development and trial design and explore cutting-edge innovations driving precision medicine forward.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Biomarkers
- Biomarker Discovery
- Biomarker Identification
- Biomarker Validation
- Clinical Biomarkers
- Pre-Clinical
- Translational Science
- Clinical Development
- Precision Medicine
- Early Detection
- Enabling Technologies
- Multiplex Technologies
- Genomic Biomarkers
- Regulation

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Biomarker Technologies
- Diagnostic Biomarkers
- Imaging Techniques
- Biomarker Analysis
- Proteomics
- Metabolomics
- Clinical Development
- Multiplex tools
- Digital Pathology

Day One

Track 1: Biomarkers for Diagnostics & Clinical Development

- Biomarker technologies for diagnostics development
  - » Multiplexing, Flow cytometry, AI/ ML for biomarker data analysis
- Multi- omics approaches to diagnostics & precision medicine
- Developing nextgen diagnostic methods & approaches
- Diagnostic-driven therapies: towards the clinic with optimised market access & patient adoption
- Transforming clinical development through biomarker driven clinical trial design and data analysis
- Precision medicine case studies for neuroscience, immunology, respiratory etc

Track 2: Identification, Qualification & Validation of Biomarkers in Translational Studies

- Biomarker discovery tools and technologies
- Biomarker strategies for patient identification
- Biomarkers to detect, predict / monitor response to treatment
- Imaging, digital and liquid biomarkers
- Scientific & regulatory considerations for the qualification analysis & validation of biomarkers
- Technologies and approaches to improve target engagement, early diagnostic biomarkers and how best to incorporate biomarkers into drug development, safety, patient stratification and clinical trials

Track 3: Precision Oncology: Companion Diagnostics, Regulations & Early Detection Technologies

- IVDR Regulations and their impact
- Companion diagnostic development
- Parallel diagnostic and drug approval strategies
- Liquid biopsy biomarkers for disease monitoring, multi-cancer screening & early detection /ultra-sensitivity/ MRD
- Latest technologies in detection and molecular characterization of: CTCs; cfDNA, ctDNA, circulating extracellular RNA; etc

Day Two

Track 1: Technologies for Biomarker Analysis

- Technology approaches, techniques & analysis - flow cytometry, mass spectrometry, proteomics, metabolomics
- Using digital biomarker to inform clinical decisions
- Biomarker assay optimization & validation
- AI/ML biomarker methods & data tools for biomarker discovery, diagnostics, prognostics, patient stratification & precision medicine

Track 2: Genomic & Multi-Omic Approaches in Biomarkers Discovery and Development

- Precision medicine approaches for personalized therapies
- Precision oncology and molecular profiling
  - » Single plex & multiplex technologies
- Biofluid-based molecular biomarkers: cfDNA, ctDNA and CTCs
- Validating & verifying genomic markers in preclinical drug development

Track 3: Precision Oncology: Biomarkers for Clinical Development and Personalized Patient Treatment

- Translating biomarker research from bench to bedside & back again
- Implementing clinical biomarkers in precision oncology
- Exploratory/clinical endpoint biomarkers needed to support clinical trials
- Genomic/ proteomic enabled trials for tailored cancer treatment
- Digital health technologies for personalized patient treatment

AGENDA AT A GLANCE

Spatial Biology for Precision Medicine

Join leaders, experts, and researchers in our Spatial Biology for Precision Medicine programme, connecting global academic & research organisations as well as pharma representatives for high-level discussions on the latest innovations in spatial research & technologies.

Forward looking visionary leaders will discuss the current state of the industry, market trends and future growth areas aiding the application of spatial technologies in the clinic as well as the rise of digital pathology.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Spatial Transcriptomics
- Spatial Proteomics
- Systems Biology
- Molecular Medicine
- Spatial Genomics
- Spatial Metabolomics

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Spatial Imaging Platforms
- Spatial Data Analysis Tools
- Spatial Genomics
- Tissue Imaging & Prep
- Single Molecule Imaging
- Bioinformatics

Day One

Track 4: Spatial Multi Omics Tools, Techniques & Approaches

- Translating spatial imaging techniques & approaches into clinics
- Transcriptomics, proteomics, genomics & metabolomics breakthrough tools, techniques & approaches for precision medicine
- Single-cell transcriptome / RNA-seq
- Multi-modality processing
- Standardization of workflows

Track 5: Spatial Bioinformatics, Data Analytics & Interpretation

- Data access, interoperability & standardization
- Data integration, visualization, handling & insight
- Cell-cell interaction
- Algorithm design for spatial data
- Accelerating the discovery & characterization of biomarkers and drug targets using spatial tools
- Overcoming challenges in multi-omic data acquisition & analysis
- Computational methods to assist in the identification, classification and visualization of complex multi model datasets
- Impacting disease research – informing assessment of treatment and action mechanisms / deciphering dynamics of cell interactions
- Adoption & utilization of AI & ML for spatial analyses in R&D

Day Two

Track 4: Applications of Spatial Research & Technologies in Biology

- Accelerating the discovery of novel biomarkers and drug targets using spatial imaging
- Case studies from the areas of:
  - » Personalized / precision medicine
  - » Oncology & Tumor microenvironment
  - » Neuroscience
  - » Cardiovascular, Immunological, Infectious diseases etc
- Part 2 – Spatial Technologies for Clinical Development
- Diagnostics applications of spatial and multi-omics tissue analysis
- Translating spatial imaging techniques & approaches into clinics
- Supporting clinical trials & patient monitoring

Track 5: Image Analysis & AI Powered Imaging for Digital Pathology & Spatial Biology

- Examining the latest developments in imaging technologies & quality
- Image format standardization
- Intersection of digital pathology & spatial biology
- Tissue imaging & analysis
- Techniques and AI guided technology – integration of AI into workflows
- Working with AI from a scientist's perspective
- Accelerating the discovery of novel biomarkers and drug targets
- Label free imaging technologies – imaging mass spec

AGENDA AT A GLANCE

Digital Pathology & AI

Gather with leading innovators in digital pathology for an in-person event in the heart of San Francisco.

Dive into the latest advancements in AI-driven image analysis & computational pathology, as well as hearing from the challenges faced and lessons learnt from those who have already implemented DP & AI into their workflow so that you can join others in shaping the future of pathology.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Digital Pathology
- Computational Pathology
- Image analysis
- Biomedical Informatics & AI
- Computational Medicine
- Pathology IT
- Immunohistochemistry
- Histopathology
- Toxicology and Safety Sciences
- NHS transformation
- Pathology
- Diagnostics

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Digital Pathology Hardware
- Scanners
- Monitors
- Digital Pathology Software
- Image analysis
- Multi-modal image analysis
- Image Management
- Cloud computing/ storage
- End to End Solutions
- LIS
- Enterprise Imaging & Healthcare IT
- AI Algorithms

Day One

Track 6: Computational Pathology & AI

- Implementing AI based precision pathology
- Advancing machine and deep learning algorithms
- Improving WSI workflow efficiency
- Pathology PACS and informatics
- Cloud computing / storage solutions
- Computational Pathology in Precision Oncology
- Deep learning application for digital biomarker discovery
- Ground truth data and technology for biomarker assessment
- Advances, challenges, benefits & future developments of Digital Pathology, and the implications for pathology practice

Day Two

Track 5: Image Analysis & AI Powered Imaging for Digital Pathology & Spatial Biology

- Examining the latest developments in imaging technologies & quality
- Image format standardization
- Intersection of digital pathology & spatial biology
- Tissue imaging & analysis
- Techniques and AI guided technology – integration of AI into workflows
- Working with AI from a scientist's perspective
- Accelerating the discovery of novel biomarkers and drug targets
- Label free imaging technologies – imaging mass spec
- Relevant spatial parameters in different model systems
- Spatial multiplexed imaging for disease characterization
- Quality assurance, control & improvement

Track 6: Utilizing Digital Pathology & AI in Pharma Research: Drug Development, Clinical Trials, Personalized Medicine

- Digitizing toxicology
- Digital image analysis in drug discovery
- AI algorithms for tissue-based endpoints
- Digital pathology on biomarker patient profiling
- AIML solutions for Biomarker discovery, detection, quantification and use in patient selection
- Case studies in: Oncology, MASH, neurology, Clinical trials

ALL PROGRAMMES

Confirmed Speakers

KEYNOTE SPEAKERS

LEROY HOOD,
Co-Founder, Institute of Systems Biology

IDA SIM,
Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley); Co-Director, UCSF UC Berkeley Joint Program in Computational Precision HEALTH

LENA BARBASH,
VP, Clinical Biomarkers And Correlative Sciences, Precision Medicine, GSK

ELSA FLORES,
Associate Center Director, Basic Science, Moffitt Cancer Center

ANIL SOOD,
Professor & Vice Chair for Translational Research, Co-Director of the Center for RNA Interference and Non-Coding RNA, MD Anderson Cancer Center

MIKE MONTALTO,
Vice President, Precision Medicine, Amgen

COREY ARNOLD,
Professor and Vice Chair of Research, Radiology; Professor, Pathology, Bioengineering, and Electrical & Computer Engineering, UCLA

LEROY HOOD
Co-Founder, Institute of Systems Biology

IDA SIM
Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley); Co-Director, UCSF UC Berkeley Joint Program in Computational Precision Health

AMRITA PATI
Executive Director, Precision Medicine Computational Biology, Amgen

ANDREA RENNINGER
Senior Director, Regulatory Affairs - Companion Diagnostic, Daiichi Sankyo

BRIAN BAKER
Executive Director - Regulatory Affairs & in Vitro Diagnostics, Regeneron

DAVID WEINGEIST
Scientific Director, Oncology Precision Medicine & Diagnostics, Johnson & Johnson Innovative Medicine

EUGEAN JIWANMALL
Senior Research Analyst for Medical Policy & Technology Assessment, Independence Blue Cross

GERALD QUON
Associate Professor, Department of Molecular and Cellular Biology, University of California, Davis

GRACE WANG
Director, Clinical Biomarker Development, Ultragenyx

I-MING WANG
Director, Translational Oncology, Pfizer

JAN SCHEJBAL
Senior Scientist I – Proteomics, QTAS – Quantitative, Translational and ADME Sciences, Abbvie

JANET JIN
Executive Director, Clinical Imaging and Diagnostics, Amgen

LENA BARBASH
Vice President, Clinical Biomarkers And Correlative Sciences, Precision Medicine, GSK

OLIVIER HARISMENDY
Vice President, Translational Data Science, Zentalis Pharmaceuticals

ROBERT GETZENBERG
Medical Director Diagnostics, Oncology, Astellas Pharma

TOWIA LIBERMANN
Director of Genomics – Proteomics Core, Beth Israel Deaconess Medical Center

VICKI PLAKS
Senior Scientific Director, Head of Cell Therapy, Oncology Translational Research, Johnson & Johnson

ANIL SOOD
Professor & Vice Chair for Translational Research, Co-Director of the Center for RNA Interference and Non-Coding RNA, MD Anderson Cancer Center

ELSA FLORES
Associate Center Director, Basic Science, Moffitt Cancer Center

VLADIMIR ROUDKO
Director, Advanced Translational Programs, AstraZeneca

IOANNIS RAGOUSSIS
Head of Genome Sciences & Professor, Department of Human Genetics, McGill Genome Centre

EVAN KELLER
Professor & Director of Single Cell Spatial Analysis Program, University of Michigan

JACK CHEN
Director, Translational Research Group Lead, Precision Medicine, AbbVie

JOHN SNOWBALL
Senior Scientist, Procter & Gamble

MICHAEL ZHANG
Director of Center for Systems Biology, University of Texas at Dallas

KOICHI HASHIKAWA
Principal Scientist Computational, Johnson & Johnson Innovative Medicine

SERGEY NOVITSKIY
Principal Scientist, Amgen

SILAS MANIATIS
Associate Director, Spatial Genomics, New York Genome Centre

STEPHEN BYERS
Professor & Associate Director, Lombardi Comprehensive Cancer Center, Georgetown University

YESIM GOKMEN POLAR
Associate Director, Pathology Cancer Program, Emory University School of Medicine

YOSHIKO HASHIKAWA
Senior Scientist, AbbVie

Confirmed Speakers

ALEXANDER KLIMOWICZ
Principal Scientist, Boehringer Ingelheim

ZHENG AO
Principal Scientist, Obsidian Therapeutics

MIKE MONTALTO
Vice President, Precision Medicine, Global Development, Amgen

ABHISHEK AGGARWAL
Director, Pathobiology, Gilead Sciences

COREY ARNOLD
Professor and Vice Chair of Research, Radiology; Professor, Pathology, Bioengineering, and Electrical & Computer Engineering, UCLA

ELIZABETH HILLMAN
Chair, Department of Imaging Sciences, Endowed Chair and Member, St Jude Children's Research Hospital

FANGYAO HU
Senior Principal Scientist AI, Safety Assessment, Genentech

GUNEET WALIA
Senior Director, Data Science & Digital Health, Johnson & Johnson Innovative Medicine

HARSH THAKER
Professor, Department of Pathology, Vice Chair, Digital and Integrative Pathology, Director, Anatomic Pathology, University of Texas Medical Branch – Galveston

JANA LIPKOVA
Assistant Professor, Pathology & Laboratory Medicine, University of California, Irvine

JOSHUA J. LEVY
Director of Digital Pathology Research, Assistant Professor of Pathology and Computational Biomedicine, Cedars Sinai Medical Center

SUZANNE COBERLY
Scientific Senior Director, Senior Director Research Pathology, Protein Homeostasis TRC, Bristol Meyers Squibb

W. DEAN WALLACE
Professor of Pathology, University of Southern California Keck School of Medicine

ZOLTAN LASZIK
Director of Digital Pathology, UCSF

NATÁLIA FARAJ MURAD
Bioinformatics Specialist, University of California, San Francisco

DIANE STEPHENSON
Vice President, Neurology; Executive Director, Critical Path for Parkinson's, Critical Path Institute

SATYA SAXENA
Director, Global Proteomics Clinical Pharmacology & Translational Medicine Neurology Business Group, Eisai

TAMMIE YEH
Senior Director and Head of Oncology Clinical Biomarkers, Oncology and Cell Therapy, Takeda Pharmaceuticals

HOUSHENG HANSEN HE
Professor, University of Toronto

SUDESHNA FISCH
Former Director, Translational Clinical Sciences, Pfizer

BOBBIE-JO WEBB-ROBERTSON
Division Director, Chief Scientist, Pacific Northwest National Laboratory

AMY L DELSON
Laboratory Architecht, Research Advocate, I-SPY Breast Cancer Clinical Trial Mark

JESUS MENDOZA MAGBANUA
Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco

JAN TOMLINSON
Patient Research Advocate, I-Spy Trial

LOKESH AGRAWAL
Chief (Acting), iorepositories and Biospecimen Research Branch (BBRB); Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute

SAM M. HANASH
Co-Director, Department of Center for Global Cancer Early Detection, The University of Texas MD Anderson Cancer Center

LAURENT AUDOLY
CEO, Co-Founder, PriveBio, Inc

ABEER OBAID
Senior Scientist, Abbvie

Day One | 27 October 2025

07:35 **Registration Opens**

08:35 **Oxford Global's Welcome Address**

08:40

Plenary Keynote Address: The Synergy Of Data-Driven Health And Data-Driven Peptide Drug Discovery

- Data-driven health employs a genome and longitudinal phenome analysis of each of many individuals to decipher their individual biological complexities and turn these insights into actionable possibilities to optimize wellness and healthy aging, to avoid disease and to gain causal insights into wellness and disease. Peptide drug discovery will employ large scale DNA synthesis to generate millions of peptide genes and then use the tools to cell and molecular biology to interrogate them individually through phenotypic and targeted selection. I will discuss these two approaches to healthcare and their synergies.

LEROY HOOD, Co-Founder,
Institute of Systems Biology

BIOMARKERS & PRECISION MEDICINE			SPATIAL BIOLOGY FOR PRECISION MEDICINE		DIGITAL PATHOLOGY & AI
CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT	CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION, & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES	CONFERENCE ROOM 3: PRECISION ONCOLOGY: COMPANION DIAGNOSTICS, REGULATIONS & EARLY DETECTION TECHNOLOGIES	CONFERENCE ROOM 4:SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES	CONFERENCE ROOM 5: SPATIAL BIOINFORMATICS, DATA ANALYTICS & INTERPRETATION	CONFERENCE ROOM 6: COMPUTATIONAL PATHOLOGY & AI
Track Chair: Anuraag Shrivastav, Professor, University of Winnipeg	*Track Chair: Satya Saxena Director, Global Proteomics Clinical Pharmacology & Translational Medicine Neurology Business Group, Eisai*	*Track Chair: TBA*	*Track Chair: TBA*	*Track Chair: TBA*	*Track Chair: TBA*

09:15

Track Keynote Address:
Evolution Of Biomarkers In Liquid Biopsies To Inform Right Dose And Right Patient

Circulating free (cf) and tumor (ct) DNA are used across stages of medicine clinical development to inform dose, identify right patients and guide patient treatments. The emerging uses of cf/ctDNA in clinical development include molecular response for dose selection, minimal residual disease and baseline characterization for patient selection. While Oncology trials often implement ctDNA, the data outside of Oncology is emerging

LENA BARBASH, VP, Clinical Biomarkers And Correlative Sciences, Precision Medicine, **GSK**

Track Keynote Address:
Updates In Predictive Biomarkers For Drug Development

(Reserved) RAJ MACHA, Associate Vice President and US Head, PKDM/Translational Medicine & Early Development, **Sanofi**

Track Keynote Address:
Evolving IVD Regulatory Landscape And Its Impact On Drug Development

BRIAN BAKER, Executive Director - Regulatory Affairs & in Vitro Diagnostics, **Regeneron**

Conference Room 4
Track Keynote Address: Decoding the p53 Pathway: Spatial Multi-Omics Approaches To Unravel Tumor Suppression, Metabolism, and Therapy Resistance

ELSA FLORES,
Associate Center Director, Basic Science,
Moffitt Cancer Center

Track Keynote Address: AI-Powered Pathology in the Continuum of Translational and Precision Medicine

Digital Pathology and AI Applications are emerging rapidly in both Pharmaceutical Drug Development through to healthcare applications. This talk will explore the critical need of biomarkers from early through late drug development and the role AI-powered pathology can play throughout this continuum. We will further explore the importance of commercial adoption and availability to Pharma's view on implementation in prospective trials for CDx applications.

MIKE MONTALTO,
Vice President, Precision Medicine Global Development,
Amgen

Q&A session & transition time between conference rooms

09:40

Diamond/Platinum Level Solution Provider

For sponsorship opportunities please contact sponsorship@oxfordglobal.com

Solution Provider Presentation

KANVAS

Senior Representative,
Kanvas Biosciences

Diamond/Platinum Level Solution Provider

For sponsorship opportunities please contact sponsorship@oxfordglobal.com

Solution Provider Presentation

10x GENOMICS

Senior Representative,
10x Genomics

Diamond/Platinum Level Solution Provider

For sponsorship opportunities please contact sponsorship@oxfordglobal.com

10:05 **MORNING BREAK & REFRESHMENTS**

1-2-1 Meetings x4 | Poster Displays

Q&A session & transition time between conference rooms

Day One | 27 October 2025

BIOMARKERS & PRECISION MEDICINE

CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT

Solution Provider Presentation

Senior Representative, **Biodesix**

Navigating Regulatory Challenges In Combined Trials: Drug And IVD Integration An An Evolving Landscape

In the rapidly evolving regulatory landscape, the integration of drugs and in vitro diagnostics (IVDs) in combined trials presents unique challenges and opportunities. This presentation will explore the regulatory hurdles and implications associated with these trials, focusing on the impact of the US FDA's Laboratory Developed Test (LDT) final rule, the European Union's In Vitro Diagnostic Regulation (IVDR), and the regulatory requirements in the Rest of the World (ROW). Attendees will gain insights into the complexities of sample testing and the strategies to navigate these regulatory frameworks effectively.

HONGDA ZHAO, Director of Precision Medicine and Digital Health in Global Regulatory Sciences, **BMS**

CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION, & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES

Solution Provider Presentation

Senior Representative, **Singular Genomics**

The Use Of PK/PD Biomarkers In Translational Studies

SUDESHNA FISCH, Former Director, Translational Clinical Sciences, **Pfizer**

CONFERENCE ROOM 3: PRECISION ONCOLOGY: COMPANION DIAGNOSTICS, REGULATIONS & EARLY DETECTION TECHNOLOGIES

Gold Level Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.com

Applying Novel Biomarker Technologies To Enable Precision Medicine Driven Clinical Development And Patient Management

Advances in precision medicine are reshaping clinical development and patient management by enabling data-driven, biomarker-guided decision-making and the delivery of targeted therapeutic interventions. Emerging technologies such as epigenomics, liquid biopsies, and AI-powered analytics are accelerating biomarker discovery and enhancing the sensitivity, specificity and accuracy of biomarker detection. Realizing the full potential of these innovations in patient management, however, will require the development of novel regulatory frameworks and pathways to support clinical implementation.

JANET JIN, Executive Director, Clinical Imaging and Diagnostics Clinical Biomarker and Diagnostics, **Amgen**

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONFERENCE ROOM 4: SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES

Solution Provider Presentation

Senior Representative, **Bruker**

Single-cell Transcriptome Approaches

SILAS MANIATIS, Associate Director, Spatial Genomics, **New York Genome Centre**

CONFERENCE ROOM 5: SPATIAL BIOINFORMATICS, DATA ANALYTICS & INTERPRETATION

Solution Provider Presentation

Senior Representative, **Ariadne AI**

Utilising Spatial Data In Biology

VLADIMIR ROUDKO, Director, Advanced Translational Programs, **AstraZeneca**

DIGITAL PATHOLOGY & AI

CONFERENCE ROOM 6: COMPUTATIONAL PATHOLOGY & AI

Gold Level Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.com

AI Image Analysis Software & Generative AI Tools For Integrated Multi Diagnostic Reports For Diagnosis & Personalized Treatment

HARSH THAKER, Professor, Vice Chair, Digital and Integrative Pathology, Director, Anatomic Pathology, **University of Texas**

11:25

11:50

Q&A session & transition time between conference rooms

Day One | 27 October 2025

BIOMARKERS & PRECISION MEDICINE

CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT

12:15

Panel Discussion: Challenges In Translating Exploratory Biomarkers Into The Clinic

- Validation and reliability
- Standardization & reproducibility
- Clinical utility & validation
- Overcoming the challenges

Moderator:

SATYA SAXENA, Director, Global Proteomics, Clinical Pharmacology and Translational Medicine, Neurology Business Group, **Eisai**

Panellists:

GRACE WANG, Director, Clinical Biomarker Development, **Ultragenyx Pharmaceutical**

ROBERT GETZENBERG, Medical Director Diagnostics, Oncology, Astellas Pharma

OLIVIER HARISMENDY, Vice President, Translational Data Science, **Zentalis Pharmaceuticals**

TAMMIE YEH, Senior Director and Head of Oncology Clinical Biomarkers, **Takeda Pharmaceuticals**

12:40

INTERACTIVE

CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION, & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES

Start Up Zone Pitches

10-Minute Presentation 1

10-Minute Presentation 2

10-Minute Presentation 3

10-Minute Presentation 4

10-Minute Presentation 5

INTERACTIVE

CONFERENCE ROOM 3: PRECISION ONCOLOGY: COMPANION DIAGNOSTICS, REGULATIONS & EARLY DETECTION TECHNOLOGIES

Panel Discussion: IVDR Regulations And Their Impact

Panellists:
BRIAN BAKER, Executive Director - Regulatory Affairs & in Vitro Diagnostics, **Regeneron**

HONGDA ZHAO, Director of Precision Medicine and Digital Health in Global Regulatory Sciences, **BMS**

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONFERENCE ROOM 4: SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES

Panel Discussion: Addressing The Future Needs Of Spatial Multi-Omics

- Future of spatial biology
- Moving towards the practical implementation of spatial findings
- How to translate into precision medicine

Panellists:
JOHN SNOWBALL, Senior Scientist, **Procter & Gamble**

ALEXANDER KLIMOWICZ, SR Research Fellow, **Boehringer Ingelheim**

SENIOR REPRESENTATIVE, **Miltenyi Biotech**

EVAN KELLER, Professor & Director of Single Cell Spatial Analysis Program, **University of Michigan**

ZHENG AO, Principal Scientist, **Obsidian Therapeutics**

INTERACTIVE

Q&A session & transition time between conference rooms

Single-Cell Transcriptome Approaches

STEPHEN BYERS, Professor & Associate Director, Lombardi Comprehensive Cancer Center, **Georgetown University**

CONFERENCE ROOM 5: SPATIAL BIOINFORMATICS, DATA ANALYTICS & INTERPRETATION

Panel Discussion: Data Sharing And Reproducing Analysis In The World Of Spatial Transcriptomics

- How to share images for reuse of data
- Establishing a set of primary data
- Use for reproducing analyses and facilitation of computational method development

Panellists:

NATÁLIA FARAJ MURAD, Bioinformatics Specialist, **University of California, San Francisco**

INTERACTIVE

DIGITAL PATHOLOGY & AI

CONFERENCE ROOM 6: COMPUTATIONAL PATHOLOGY & AI

Panel Discussion: Real World Learning From Deploying Digital And Computational Pathology At Scale

Panellists:
GUNEET WALIA, Senior Director, Data Science & Digital Health, **Johnson & Johnson Innovative Medicine**

Q&A session & transition time between conference rooms

Computational Pathology Apps Deployment & Challenges - Integration With Existing Workflows And Hardare/Software Set-Ups

ZOLTAN LASZIK, Director of Digital Pathology, **UCSF**

1:05

Conference Room 1:
Panel Discussion: Building the Next Era of Precision Medicine: Stakeholder Collaboration Across Biomarkers, Diagnostics, Genomics And Therapeutic Innovation

Panellists
LEROY HOOD, Co-Founder, **Institute of Systems Biology**
ROBERT GETZENBERG, Medical Director Diagnostics, Oncology, **Astellas Pharma**

INTERACTIVE

Patient / Research Advocate Perspective - The I-SPY Breast Cancer Clinical Trial

- Research advocate - The use of biomarkers for the trial – germline genetics, tumor genetics, response predictive subtypes, proteomics, liquid biopsy (ctDNA, oncRNA), imaging, etc., to assess risk, monitor resistance and response, etc.
- Patient advocate - patient experience on the trial; patient-reported outcomes, etc.

AMY L DELSON, Research Patient Advocate, **I-SPY Trial**

JAN TOMLINSON, Patient Research Advocate, **I-Spy Trial**

MARK JESUS MENDOZA MAGBANUA, Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center, **University of California San Francisco**

INTERACTIVE

Day One | 27 October 2025

	BIOMARKERS & PRECISION MEDICINE			SPATIAL BIOLOGY FOR PRECISION MEDICINE		DIGITAL PATHOLOGY & AI
	CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT	CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION, & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES	CONFERENCE ROOM 3: PRECISION ONCOLOGY: COMPANION DIAGNOSTICS, REGULATIONS & EARLY DETECTION TECHNOLOGIES	CONFERENCE ROOM 4: SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES	CONFERENCE ROOM 5: SPATIAL BIOINFORMATICS, DATA ANALYTICS & INTERPRETATION	CONFERENCE ROOM 6: COMPUTATIONAL PATHOLOGY & AI
1:35	**LUNCH BREAK & REFRESHMENTS**					
	1-2-1 Meetings x3			Poster Displays		
2:35	**Solution Provider Presentation** BIOIVT Senior Representative, **BioIVT**	**Solution Provider Presentation** Lunaphore a biotechne brand Senior Representative, **Lunaphore Technologies**	**Solution Provider Presentation** DISCOVERY LIFE SCIENCES Senior Representative, **Discovery Life Sciences**	**Solution Provider Presentation** Miltenyi Biotec Senior Representative, **Miltenyi Biotec**	**Solution Provider Presentation** vizgen Senior Representative, **Vizgen**	**Silver Level Solution Provider** *For sponsorship opportunities please contact sponsorship@oxfordglobal.com*

Q&A session & transition time between conference rooms

3:00	**Patient Focused Drug Development For Parkinson's Disease** Early intervention strategies are key to halting the relentless progression of brain diseases. Biomarker informed clinical trials are now emerging across a range of neurological diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease and ALS. This presentation will highlight the role of precompetitive global collaborations to advance the regulatory maturity of biomarkers to support innovative treatments for neurodegenerative diseases. DIANE STEPHENSON, Vice President, Neurology; Executive Director, **Critical Path for Parkinson's, Critical Path Institute**	**Immunological Biomarkers Of Response And Resistance To Treatment With Cabozantinib And Nivolumab In Recurrent Endometrial Cancer** VLADIMIR ROUDKO, Director, Advanced Translational Programs, **AstraZeneca**	**Innovative Diagnostic Solutions: Maximizing Opportunities in Bladder Cancer Treatment** DAVID WEINGEIST, Scientific Director, Oncology Precision Medicine & Diagnostics, **Johnson & Johnson Innovative Medicine**	**Multiomic Modular Network Approach For Target ID, Patient Stratification, & Combo Rationale In IBD** • Gene module network is deconstructed using scRNAseq data from IBD patient samples. • Highly multiplexed spatial omics approach (CosMx) recapitulated granular cell types in space. • Spatial domain (niche) highlighted unique spatial interactions in IBD. KOICHI HASHIKAWA, Principal Scientist Computational, **Johnson & Johnson Innovative Medicine**	**Single Cell Metabolomics Technology & Spatial Omics Data Resource** • Spatial high-resolution in situ metabolomic finger-prints fine tissue-sections revealing intercellular heterogeneity and tissue organization • A comprehensive and flexible platform combining high-spatial-resolution imaging mass spectrometry and a set of computational algorithms that can display multiscale and multicolor tissue tomography • Demonstration of SEAM application in delineating a consistent pattern of metabolic zonation in mouse liver and the metabolic profile in the human fibrotic liver • Introduce a comprehensive Spatial Omics Data/Tool resource MICHAEL ZHANG, Director of Center for Systems Biology, **University of Texas at Dallas**	**Foundational Models For Survival Prediction In Oncology** Foundational models enable learning from unlabeled data & fine-tuning with minimal labeled samples-improving accuracy, generalizability, & reducing bias. However, most FMs are tested on simple classification tasks, while prognostic prediction-where labeled data are scarce-remains underexplored. We benchmark 10 recent FMs across 4 consortia for survival prediction in oncology, evaluating performance, generalization, & interpretability. We found that multimodal FMs can learn general cancer hallmarks & deliver robust predictions, even for rare diseases & cancers unseen during training highlighting their potential as generalist oncology models. JANA LIPKOVA, Assistant Professor, Pathology & Laboratory Medicine, **University of California, Irvine**

Day One | 27 October 2025

BIOMARKERS & PRECISION MEDICINE			SPATIAL BIOLOGY FOR PRECISION MEDICINE		DIGITAL PATHOLOGY & AI
CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT	CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION, & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES	CONFERENCE ROOM 3: PRECISION ONCOLOGY: COMPANION DIAGNOSTICS, REGULATIONS & EARLY DETECTION TECHNOLOGIES	CONFERENCE ROOM 4:SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES	CONFERENCE ROOM 5: SPATIAL BIOINFORMATICS, DATA ANALYTICS & INTERPRETATION	CONFERENCE ROOM 6: COMPUTATIONAL PATHOLOGY & AI
Solution Provider Presentation Senior Representative, Millipore Sigma	**Solution Provider Presentation** Senior Representative, **Standard Biotools**	**Solution Provider Presentation** *For sponsorship opportunities please contact sponsorship@oxfordglobal.com*	**Solution Provider Presentation** Senior Representative, **Rarecyte**	**Solution Provider Presentation** Senior Representative, **Akoya Biosciences**	**Solution Provider Presentation** Senior Representative, **Leica Biosystems**

3:25

Q&A session & transition time between conference rooms

What Do Clinical Biomarkers Bring To The Table? Dr. Yeh will be presenting an overview on the value and utility of including biomarkers in clinical trials despite the additional resources and complexities that are introduced. She will also share specific case examples showing how clinical biomarkers have influenced and impacted specific oncology clinical trials, ranging from patient selection to end-of-treatment sample analyses to inclusion as a primary endpoint. TAMMIE YEH, Senior Director and Head of Oncology Clinical Biomarkers, **Takeda Pharmaceuticals**	**Aptamer-Based 11k SomaScan Proteomics Driving Non-Invasive Biomarker Discovery and Precision Medicine** Novel proteomics platforms have been developed to drive precision medicine and biomarker discovery. We will present our efforts on non-invasive biomarkers for a broad range of clinically highly relevant diagnostic, predictive, and prognostic indications (oncology, autoimmune diseases, neurodegenerative diseases) using the currently most comprehensive, high throughput proteomics platform, SomaScan v5.0, measuring 11,000 proteins. TOWIA LIBERMANN, Director of Genomics – Proteomics Core, **Beth Israel Deaconess Medical Center**	**A Multidisciplinary Approach Towards Targeting Cancer Therapies With Precision** Precision approaches are being applied in almost all areas of therapeutic development. Cellular components such as tissue restricted tight junction proteins are being utilized to target therapy in patients with diseases for which there are limited options, such as gastric/GEJ cancer. Implementation of such approaches requires unique efforts focused on the testing and clinical environments. ROBERT GETZENBERG, Medical Director Diagnostics, Oncology, **Astellas Pharma**	**Landscaping Next Generation Spatial Platforms Utilizing Hair Follicle Niche** • Spatial transcriptomics enables the understanding of complex biological systems. It allows one to examine intact biological tissues, answering the elusive question of where, not just what, is happening. • However, multiple platforms are available to perform Spatial Transcriptomics. We utilize the hair follicle's spatial complexity to compare and contrast 6 leading Spatial Transcriptomics platforms and provide an overview of our experiences. JOHN SNOWBALL, Senior Scientist, **Procter & Gamble**	**Applying Spatial Analytics To Urologic Cancers** • Spatial analytics offers multiple opportunities to incorporate spatially-derived parameters as biomarkers. • Multiple methods exist to analyze spatially-derived parameters including spatial localization of transcript signatures, cell to cell distance, and cellular niche formation. • These methods will be demonstrated in urologic cancers. EVAN KELLER, Professor & Director of Single Cell Spatial Analysis Program, **University of Michigan**	**Digitizing Your Biospecimen Repository: Why, How And When?** Effective biorepository collections require labor intensive and costly resources dedicated to patient consenting, specimen processing and biospecimen storage. A weakness of many biorepositories is the frequent underutilized of these specimens. We have developed a highly functional biorepository software that includes digital images of all collected samples to enable rapid review of the material for quicker sample selection and improved utilization. W. DEAN WALLACE, Professor of Pathology **University of Southern California Keck School of Medicine**

3:50

Q&A session & transition time between conference rooms

4:15 **AFTERNOON NETWORKING BREAK & REFRESHMENTS**

1-2-1 Meetings x4 | Poster Displays

Day One | 27 October 2025

BIOMARKERS & PRECISION MEDICINE

CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT

Role of Biospecimen Science and Biobanking in Understanding Precision Medicine in Cancer

Biospecimens are the essential starting materials for the biomarker assays that enable precision medicine and preanalytical factors can directly influence molecular results from assays conducted for basic research, biomarker discovery, and biomarker validation, and can also influence the development of clinical assays. This talk will focus on role of biospecimen science in context of cfDNA as a predictive, prognostic clinical biomarker, and cover briefly The Cancer MoonshotSM Biobank (moonshotbiobank.cancer.gov), which is a National Cancer Institute (NCI)-sponsored study that aims to accelerate cancer research through the collection of longitudinal liquid biopsy specimens and tissues from patients with advanced cancer receiving standard of care therapy.

LOKESH AGRAWAL, Chief (Acting), iorepositories and Biospecimen Research Branch (BBRB); Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, **National Cancer Institute**

CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION, & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES

Targeted Therapeutics In Fibroinflammatory Diseases - A Precision Medicine Framework

PriveBio is a precision medicine biotech focused on discovering and developing novel medicines to cure fibro-inflammation in cardiometabolic, renal diseases and obesity that address unmet medical need in the post-GLP1 era. Powered by proprietary high dimensionality patient-derived data, the company is developing a portfolio of first-in-class therapeutics and blood-based detection assays to deliver impact for patients as efficiently as possible.

LAURENT AUDOLY, CEO, Co-Founder **PriveBio, Inc**

CONFERENCE ROOM 3: PRECISION ONCOLOGY: COMPANION DIAGNOSTICS, REGULATIONS & EARLY DETECTION TECHNOLOGIES

A Multi-Cancer Stratification Test (MCaST) To Tailor Cancer Screening Based On Personalized Risk Profile

- Cancer screening at the present time is limited to a few common cancers in the US and is largely based on age. MCaST is a protein based blood test intended to determine risk for nine cancers representing 85% of all cancer diagnoses. The Performance and cost effectiveness of MCaST will be presented.

SAM M. HANASH, Co-Director, Department of Center for Global Cancer Early Detection, **The University of Texas MD Anderson Cancer Center**

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONFERENCE ROOM 4:SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES

Spatial Transcriptomic Analysis Of Breast Cancer Patients After Endocrine/CDK4/6 Treatments: Deconvoluting The Tumor Microenvironment

- We explored how the tumor microenvironment (TME) affects resistance to CDK4/6 inhibitors in ER+ breast cancer using spatial transcriptomics on tumor samples.
- Higher levels of immune cells and cancer-associated fibroblasts (CAF) were correlated with progression suggesting the crucial role of TME in driving resistance to CDK4/6 inhibitors. The study identifies potential targets to overcome therapy resistance.

YESIM GOKMEN POLAR, Associate Director, Pathology Cancer Program, **Emory University School of Medicine**

CONFERENCE ROOM 5: SPATIAL BIOINFORMATICS, DATA ANALYTICS & INTERPRETATION

Spatial Profiling of p16+ Microenvironments in Postmenopausal Ovaries Reveals Senescence Signatures with Diagnostic and Therapeutic Potential

- How spatial transcriptomics can uncover senescent (p16) cell niches in postmenopausal ovaries and reveal new insights into reproductive aging
- By integrating histological imaging with molecular data, we identified unique senescence signatures with diagnostic and therapeutic potential
- I'll walk you through data organization, analysis, and validation across patients — showing how these findings can be robust and clinically relevant

NATÁLIA FARAJ MURAD, Bioinformatics Specialist, **University of California, San Francisco**

DIGITAL PATHOLOGY & AI

CONFERENCE ROOM 6: COMPUTATIONAL PATHOLOGY & AI

Applications Of AI For Prostate Histology

COREY ARNOLD, Professor and Vice Chair of Research, Radiology; Professor, Pathology, Bioengineering, and Electrical & Computer Engineering, **UCLA**

5:35 *Q&A session & transition time between conference rooms*

6:00 **Conference Room 1: Fireside Chat with Industry Leader**

6:30 **NETWORKING DRINKS & END OF DAY ONE**

Day Two | 28 October 2025

	BIOMARKERS & PRECISION MEDICINE	SPATIAL BIOLOGY FOR PRECISION MEDICINE	DIGITAL PATHOLOGY & AI
07:35	**Badge Collection**		

DIRECTORS BREAKFAST ROUNDTABLES

08:05	Biomarkers	Biomarkers	Biomarkers	Spatial Biology	Spatial Biology	Digital Pathology & AI	Digital Pathology & AI
	Precision Medicine in Novel Therapeutics	**Translational Biomarkers In Clinical Trials For Immunotherapy**	**Separation Of Reverse And Forward Translation In Pharma: The Case Of Data Scientists**	**Advancing Spatial Imaging Techniques In Novel Development Of Drugs**	**Tissue Imaging And Analysis Using Advanced Spatial Profiling Techniques**	**Standardization In Digital Pathology: A Necessary Step or a Barrier to Innovation?**	**The Role of AI In Pathologist Workflows: Enhancer or Replacement? Who Should Take The Lead**
	Moderator: SUDESHNA FISCH, Former Director, Translational Clinical Sciences, **Pfizer**	**Moderator:** TOWIA LIBERMANN, Director of Genomics – Proteomics	**Moderator** OLIVIER HARISMENDY, Vice President, Translational Data Science, **Zentalis Pharmaceuticals**	**Moderator:** ABEER OBAID, Senior Scientist I, **AbbVie**	**Moderator:** ZHENG AO, Principal Scientist, **Obsidian Therapeutics**	**Moderator TBA**	**Moderator TBA**

Plenary Keynote Address - Harnessing Computational Tools In Precision Medicine: Implementation And Future Directions

08:40 Achieving precision health will require AI advances spanning biomedical discovery to healthcare delivery. Yet the digital health ecosystem is siloed between discovery and delivery as well as between remote monitoring and in-person clinical care. This talk discusses how digital public utility -- as exemplified by JupyterHealth, an open-source platform that extends Jupyter tools to healthcare – enables real-world precision health solutions.

IDA SIM, Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley); Co-Director, **UCSF UC Berkeley Joint Program in Computational Precision Health**

09:10	*Track Chair: Jan Schejbal Senior Scientist I - Proteomics, QTAS – Quantitative, Translational and ADME Sciences, Abbvie*	*Track Chair: TBA*	*Track Chair: Anuraag Shrivastav, Professor, University of Winnipeg*	*Track Chair: TBA*	*Track Chair: TBA*	*Track Chair: TBA*
	Track Keynote: **A Novel Peptide-Driven Proteomics Platform To Overcome Biomarker Discovery Challenges In Early-Phase Clinical Trials.**	**Track Keynote:** **Decoding Response and Resistance: Multi-Omic, Multimodal Analytics In Clinical Trials**	**Track Keynote:** **Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer**	**Track Keynote:** **Decoding Tumor Microenvironments With Spatial Technologies**	**Track Keynote:** **High throughput Multiplexed IHC Imaging Of Cleared Human Brain**	**Track Keynote:** **Building A Strategy For AI Algorithm Development & Implementation For Tissue Based Endpoints**
	Biomarkers play a critical role in early phases of drug development by providing evidence of biological engagement and intended mechanism of action of the drug in human systems. Here, we describe the utility of an orthogonal network-informed unbiased peptide-driven global proteomics strategy to facilitate the identification of potential mechanism of action (MoA) and pharmacodynamic (PD) biomarkers in Early-Phase clinical trial samples.	This talk explores how multi-omic and multimodal data analysis is transforming clinical trials. We'll examine analytical paradigms for uncovering mechanisms of response and resistance, and how these insights drive both translation and reverse translation. The integration of emerging technologies and AI/ML approaches will be highlighted, offering a forward-looking view on precision biomarker strategies in therapeutic development.	Azenosertib is a potential best-in-class WEE1 inhibitor with pre-clinical efficacy in multiple indications and currently under development in Cyclin E1 Positive Platinum Resistant Ovarian Cancer. Treatment with azenosertib inhibits the G1S and G2M cell cycle checkpoints and factors driving up replication stress, such as Cyclin E1 over-expression, can predict sensitivity. Dr. Harismendy will review the preclinical and retrospective clinical data that led to the FDA Fast Track Designation in Cyclin E1 positive ovarian cancer and discuss implications for the current clinical development strategy.	Tissue-clearing combined with immunostaining affords the ability to map cellular-level structures within large, intact tissue samples. However, imaging can be prohibitively slow, repetitive staining is almost impossible and resulting datasets are huge. I will present methods that enable ultra-high throughput light-sheet imaging, combined with multiplexed immunostaining strategies that can enable single-pass, high-content imaging of samples including the whole human brain.	
	SATYA SAXENA, Director, Global Proteomics Clinical Pharmacology and Translational Medicine, Neurology Business Group, **Eisai**	AMRITA PATI, Executive Director, Precision Medicine Computational Biology, **Amgen**	OLIVIER HARISMENDY, Vice President, Translational Data Science, **Zentalis Pharmaceuticals**	ANIL SOOD, Professor & Vice Chair for Translational Research, Co-Director of the Center for RNA Interference and Non-Coding **MD Anderson Cancer Center**	ELIZABETH HILLMAN, Chair, Department of Imaging Sciences, Endowed Chair and Member, **St Jude Children's Research Hospital**	*(Reserved)* MICHAEL SURACE, Director, Cancer Biomarker Development, TM, EO, **AstraZeneca**

Q&A session & transition time between conference rooms

Day Two | 28 October 2025

	BIOMARKERS & PRECISION MEDICINE			SPATIAL BIOLOGY FOR PRECISION MEDICINE		DIGITAL PATHOLOGY & AI
	CONFERENCE ROOM 1: TECHNOLOGIES FOR BIOMARKER ANALYSIS	CONFERENCE ROOM 2: GENOMICS & MULTI-OMIC APPROACHES IN BIOMARKER DISCOVERY & DEVELOPMENT	CONFERENCE ROOM 3: PRECISION ONCOLOGY: BIOMARKERS FOR CLINICAL DEVELOPMENT & PERSONALIZED PATIENT TREATMENT	CONFERENCE ROOM 4: APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN BIOLOGY	CONFERENCE ROOM 5: IMAGE ANALYSIS, AI-POWERED IMAGING FOR DIGITAL PATHOLOGY & SPATIAL BIOLOGY	CONFERENCE ROOM 6: UTILIZING DIGITAL PATHOLOGY IN PHARMA: DRUG DEVELOPMENT, CLINICAL TRIALS & PERSONALIZED MEDICINE
09:35	**Diamond/Platinum Level Solution Provider Presentation** *For sponsorship opportunities please contact sponsorship@oxfordglobal.com*	**Diamond/Platinum Level Solution Provider Presentation** *For sponsorship opportunities please contact sponsorship@oxfordglobal.com*	**Diamond/Platinum Level Solution Provider Presentation** *For sponsorship opportunities please contact sponsorship@oxfordglobal.com*	**Diamond/Platinum Level Solution Provider Presentation** *For sponsorship opportunities please contact sponsorship@oxfordglobal.com*		**Diamond/Platinum Level Solution Provider Presentation** *For sponsorship opportunities please contact sponsorship@oxfordglobal.com*
10:00	**MORNING BREAK & REFRESHMENTS**					
	1-2-1 Meetings x4			Poster Displays		
11:20	**Solution Provider Presentation** Olink Senior Representative, **Olink**	**Solution Provider Presentation** SYNCELL Senior Representative, **Syncell**	**Gold Level Solution Provider Presentation** *For sponsorship opportunities please contact sponsorship@oxfordglobal.com*	**Solution Provider Presentation** HAMAMATSU PHOTON IS OUR BUSINESS Senior Representative, **Hamamatsu**	**Solution Provider Presentation** PRECISION for medicine Senior Representative, **Precision for Medicine**	**Gold Level Solution Provider Presentation** *For sponsorship opportunities please contact sponsorship@oxfordglobal.com*
	Q&A session & transition time between conference rooms					
11:45	**Proteomic Based Biomarker Analysis** Mass spectrometry (MS)-based proteomics is essential in biomarker discovery, yet many projects focus solely on blood. In my talk, I will present our efforts to look for biomarkers beyond blood, highlighting how advancements in MS sensitivity and throughput enable us to probe limited samples like tears and tape strips, broadening the horizons of biomarker discovery. JAN SCHEJBAL, Senior Scientist I – Proteomics, QTAS – Quantitative, Translational and ADME Sciences, **AbbVie**	**Utilizing Multi-Omics Data To Ensure Clinical Utility Of Tests** EUGEAN JIWANMALL, Senior Research Analyst for Medical Policy & Technology Assessment, **Independence Blue Cross**	**Clinical Biomarker Development In Immuno-Oncology** VICKI PLAKS, Senior Scientific Director, Head of Cell Therapy, Oncology Translational Research, **Johnson & Johnson Innovative Medicine**	**Spatial Transcriptomic Technologies** IOANNIS RAGOUSSIS, Head of Genome Sciences, Professor, Department of Human Genetics, **McGill Genome Centre**	**Combining 3D Tissue Imaging With Multi-Modal Spatial Analysis For Cell Therapy Pre-Clinical Development** ZHENG AO, Principal Scientist, **Obsidian Therapeutics**	**Tissue-Based Imaging and Analytical Workflows: Unlocking Target Biology Insights In Early-Phase Clinical Trials** This presentation explores advanced tissue-based imaging and analytics in early-phase clinical trials, highlighting innovations that enable precise biomarker identification. Through case studies, we'll show how iterative analysis pipelines enhance translational research and decision-making. We'll also address challenges in complex study analysis and strategies for implementing scalable, reproducible imaging solutions that accelerate discovery-to-clinic translation. ABHISHEK AGGARWAL, Director, Pathobiology, **Gilead**
	Q&A session & transition time between conference rooms					
12:10	**Solution Provider Presentation** LEVITAS BIO Senior Representative, **Levitas Bio**	**Solution Provider Presentation** mission bio Senior Representative, **Mission Bio**	**Silver Level Solution Provider Presentation** *For sponsorship opportunities please contact sponsorship@oxfordglobal.com*	**Solution Provider Presentation** ENABLE MEDICINE Senior Representative, **Enable Medicine**	**Solution Provider Presentation** CONCEPT LIFE SCIENCES Senior Representative, **Concept Life Sciences**	**Silver Level Solution Provider Presentation** *For sponsorship opportunities please contact sponsorship@oxfordglobal.com*
	Q&A session & transition time between conference rooms					

Day Two | 28 October 2025

BIOMARKERS & PRECISION MEDICINE			SPATIAL BIOLOGY FOR PRECISION MEDICINE		DIGITAL PATHOLOGY & AI
CONFERENCE ROOM 1: TECHNOLOGIES FOR BIOMARKER ANALYSIS	CONFERENCE ROOM 2: GENOMICS & MULTI-OMIC APPROACHES IN BIOMARKER DISCOVERY & DEVELOPMENT	CONFERENCE ROOM 3: PRECISION ONCOLOGY: BIOMARKERS FOR CLINICAL DEVELOPMENT & PERSONALIZED PATIENT TREATMENT	CONFERENCE ROOM 4: APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN BIOLOGY	CONFERENCE ROOM 5: IMAGE ANALYSIS, AI-POWERED IMAGING FOR DIGITAL PATHOLOGY & SPATIAL BIOLOGY	CONFERENCE ROOM 6: UTILIZING DIGITAL PATHOLOGY IN PHARMA: DRUG DEVELOPMENT, CLINICAL TRIALS & PERSONALIZED MEDICINE

12:35

Conference Room 1: Plenary Panel Discussion - AI-Powered Precision Medicine:
- The role of AI in personalized medicine
- Challenges of implementing AI in real-world settings

Moderated by:
LAURENT AUDOLY, CEO, Co-Founder, **PriveBio, Inc**
Panellists:
IDA SIM, Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley), UCSF Chief Research Informatics Officer, Co-Director, **UCSF UC Berkeley Joint Program in Computational Precision Health**
MIKE MONTALTO, Vice President, Precision Medicine, Global Development, **Amgen**

Spatial Multimodal Analysis for Histologic Characterization of the Tumor Microenvironment
- This talk presents preliminary work integrating H&E histology, spatial transcriptomics, and complementary assays using AI-driven spatial multiomics. We show how ST-informed H&E phenotyping reveals gene expression signatures and potential prognostic markers.
- By combining spatial modalities, we uncover interactions within the tumor microenvironment (TME). Key challenges and future directions in data quality, interpretability, and clinical translation are discussed.

JOSHUA J. LEVY, Director of Digital Pathology Research Assistant Professor of Pathology and Computational Biomedicine, **Cedars Sinai Medical Center**

1:05

LUNCH BREAK & REFRESHMENTS

1-2-1 Meetings x3 | Poster Displays

2:05

Solution Provider Presentation
Cerba Research
Senior Representative, **Cerba Research**

Solution Provider Presentation
BIOGNOSYS NEXT GENERATION PROTEOMICS
Senior Representative, **Biognosys**

Bronze Level Solution Provider Presentation
For sponsorship opportunities please contact sponsorship@oxfordglobal.com

Solution Provider Presentation
ELUCIDATE BIOTECHNOLOGIES
Senior Representative, **Elucidate Biotechnologies**

Bronze Level Solution Provider Presentation
For sponsorship opportunities please contact sponsorship@oxfordglobal.com

Bronze Level Solution Provider Presentation
For sponsorship opportunities please contact sponsorship@oxfordglobal.com

2:30

Panel Discussion: Application and Integration Of Proteomic Biomarkers In Precision Medicine
- Biomarker discovery
- Diagnostics and prognostics
- Patient stratification and precision medicine

Panellists:
SATYA SAXENA, Director, Global Proteomics, Clinical Pharmacology and Translational Medicine, Neurology
TOWIA LIBERMANN, Director of Genomics – Proteomics Core, **Beth Israel Deaconess Medical Center**
JAN SCHEJBAL, Senior Scientist I – Proteomics, QTAS – Quantitative, Translational and ADME Sciences, **AbbVie**
SAM M. HANASH, Co-Director, Department of Center for Global Cancer Early Detection, **The University of Texas MD Anderson Cancer Center**
LOKESH AGRAWAL, Chief (Acting), iorepositories and Biospecimen Research Branch (BBRB); Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, **National Cancer Institute**

INTERACTIVE

Panel Discussion: Application and integration of AI/ML in Biomarker Science
- Biomarker discovery
- Diagnostics and prognostics
- Patient stratification and precision medicine

Panellists:
AMRITA PATI, Senior Director, Precision Medicine Computational Biology, **Amgen**
OLIVIER HARISMENDY, Vice President, Translational Data Science, **Zentalis Pharmaceuticals**
BOBBIE-JO WEBB-ROBERTSON, Division Director, Chief Scientist, **Pacific Northwest National Laboratory**

INTERACTIVE

Panel Discussion: Implementing Patient-Centric Biomarkers In Clinical Trials
- The ways to engage with patients in a biomarker setting
- Strategic planning for clinical trials
- Multi-omics single cell analysis on immune cells- promises and challenges

Panellists:
ROBERT GETZENBERG, Medical Director diagnostics, Oncology, **Astellas Pharma**

INTERACTIVE

Panel Discussion: Moving From Discovery Phases To Clinical Trials In Spatial Biology
- Utility of spatial technologies in discovery
- Integration of spatial technology in the clinic
- Methods, strategies & future directions

Panellists:
YESIM GOKMEN, Polar Associate Director, **Emory University School of Medicine**
JACK CHEN, Director Translational Research Group Lead, **AbbVie**

INTERACTIVE

Spatial Multi-Omics: Mapping Immune Landscapes in Respiratory Disease
ALEXANDER KLIMOWICZ, SR Research Fellow, Immunology & Respiratory Disease Research, **Boehringer Ingelheim Pharmaceuticals**

Panel Discussion: Computational Methods To Assist In The Identification, Classification & Visualization Of Complex Multi Model Datasets
- Data access, interoperability & standardization
- Overcoming challenges in multi-omic data acquisition & analysis

Panellists:
KOICHI HASHIKAWA, Principal Scientist Computational, **Johnson & Johnson Innovative Medicine**
JANA LIPKOVA, Assistant Professor, Pathology & Laboratory Medicine, **University of California, Irvine**

INTERACTIVE

Digitalizing Toxicological Patholgy And Nonclinical Studies In Drug Development
FANGYAO HU, Senior Principal Scientist AI, Safety Assessment, **Genentec**

Q&A session & transition time between conference rooms

Computational Pathology In Precision Oncology
GUNEET WALIA, Senior Director, Data Science & Digital Health, **Johnson & Johnson Innovative Medicine**

2:55

Day Two | 28 October 2025

	BIOMARKERS & PRECISION MEDICINE			SPATIAL BIOLOGY FOR PRECISION MEDICINE		DIGITAL PATHOLOGY & AI
	CONFERENCE ROOM 1: TECHNOLOGIES FOR BIOMARKER ANALYSIS	CONFERENCE ROOM 2: GENOMICS & MULTI-OMIC APPROACHES IN BIOMARKER DISCOVERY & DEVELOPMENT	CONFERENCE ROOM 3: PRECISION ONCOLOGY: BIOMARKERS FOR CLINICAL DEVELOPMENT & PERSONALIZED PATIENT TREATMENT	CONFERENCE ROOM 4: APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN BIOLOGY	CONFERENCE ROOM 5: IMAGE ANALYSIS, AI-POWERED IMAGING FOR DIGITAL PATHOLOGY & SPATIAL BIOLOGY	CONFERENCE ROOM 6: UTILIZING DIGITAL PATHOLOGY IN PHARMA: DRUG DEVELOPMENT, CLINICAL TRIALS & PERSONALIZED MEDICINE
	Q&A session & transition time between conference rooms					
3:20	**Complement Proteins: Potential Biomarkers for Islet Autoimmunity and Type 1 Diabetes Onset** Type 1 diabetes (T1D) results from autoimmune β-cell destruction. We found that reduced complement protein levels precede the appearance of islet autoantibodies and persist through T1D onset. Children progressing to T1D show lower complement proteins than non-progressors, highlighting the complement pathway as a promising biomarker and therapeutic target for early prediction and prevention. BOBBIE-JO WEBB-ROBERTSON, Division Director, Chief Scientist, **Pacific Northwest National Laboratory**	**Biomarker Discovery And Strategy For Rare Disease Drug Development** Drug development for rare diseases presents unique challenges, including small patient populations, clinical and genetic heterogeneity, limited natural history data, and a scarcity of nonclinical and clinical studies. At Ultragenyx, we have implemented an integrated biomarker strategy across our development pipeline. Established biomarker assays are employed in multiple preclinical and clinical studies to elucidate disease mechanisms, assess pharmacodynamic responses, inform dose selection, and support decision-making throughout the development process. GRACE WANG, Director, Clinical Biomarker Development, **Ultragenyx Pharmaceutical**	**Biomarker Discovery And Development For KRAS Inhibitors** • Successes of KRASG12C-targeting inhibitors sotorasib and adagrasib generated tremendous excitement although they only benefit a portion of all KRAS mutant cancer patients and resistance to treatment invariably develops. • Arduous work is ongoing in identifying pan-KRAS inhibitors which could benefit more patients and rationally designing combination strategies to overcome resistance. • Biomarkers, especially ctDNA, play a key role in informing all these critical KRAS drug development activities. This presentation will summarize key recent findings and point out future directions in the KRAS-related biomarker space with a goal of achieving more advanced precision medicine. I-MING WANG, Director, Translational Oncology, **Pfizer**	**Spatial Analysis Of Immune Infiltration In The TME** SERGEY NOVITSKIY, Principal Scientist, **Amgen**	**Spatial Characterization Cf Intraductal Carcinoma/ Cribriform Architecture Of Prostate Cancer** • We applied spatial transcriptomics, OncoScan, and deep learning to profile 30 prostate cancers with intraductal carcinoma (IDC) or cribriform architecture (CA). Our spatially resolved analyses uncovered distinct, yet overlapping, molecular programs between IDC and CA. • Machine learning identified a CA-specific gene signature validated in external cohorts. Genomic analyses revealed shared alterations with metastases, suggesting IDC and CA as clonal origins of progression, with clinical implications for risk stratification and precision therapy. HOUSHENG HANSEN HE, Professor, **University of Toronto**	**Workshop: Digital Pathology In Pharma - Overcoming Integration Strategies & Future Proofing** **Moderator:** GUNEET WALIA, Senior Director, Data Science & Digital Health, **Johnson & Johnson Innovative Medicine** **Panellists:** SUZANNE COBERLY, Senior Director Research Pathology, Protein Homeostasis TRC, **Bristol Meyers Squibb**
	Q&A session & transition time between conference rooms					
3:45	**Biomarker Technologies For Diagnostics Development** (RESERVED) JAI PANDEY, Global Head, Device Regulatory For Diagnostics & Digital Health, **Sanofi**	**Using Early Somatic Variants To Predict Risk Of Late Stage Psychiatric Disorders** GERALD QUON, Associate Professor, Department of Molecular and Cellular Biology, **University of California, Davis**	**Designing Patient Centric Trials With Biomarker Defined Populations** SPEAKER TBA	**Spatial & Single Cell Technologies** YOSHIKO HASHIKAWA, Senior Scientist, **AbbVie**	*Attendees are welcome to join co-located sessions*	**Workshop Continued**
4:10	**END OF CONFERENCE**					

VENUE INFORMATION

The Westin St. Francis San Francisco on Union Square

The Westin St. Francis has been offering guests a warm welcome and an enriching, restorative stay since its opening in 1904. With its turn-of-the-20th-century European style, this hotel in San Francisco's downtown area, blends the elegance of oak-paneled restaurants and the stately grandeur of the lobby with a $45 million reinvention of the Landmark Building guest suites, ushering in a new chapter for this storied destination.

As the only hotel on Union Square, SF, it is close to the Financial District and Moscone Convention Center, and with cable cars just outside the front doors, they are at the intersection of the glorious past and vibrant present of this incredible city.

Reduced rate rooms can be purchased here.

WESTIN®
HOTELS & RESORTS

335 Powell St, San Francisco, CA 94102, United States

Venue Website